Alloksys Life Sciences

Alloksys Life Sciences is a private, clinical-stage biotechnology company focused on transforming critical care medicine through its proprietary enzyme therapy, RESCAP® (rescuing alkaline phosphatase). The company's mission is to develop innovative treatments that expedite patient recovery, reduce severe complications like acute kidney injury, and lower mortality in intensive care settings. With positive interim Phase IIb results and ongoing Phase IIb/III trials, Alloksys is strategically targeting high-unmet-need indications in perioperative care, aiming to bring a first-in-class therapeutic to a rapidly growing critical care market.

Proprietary alkaline phosphatase (AP) enzyme platform, branded RESCAP®, which detoxifies bacterial toxins, reduces inflammation, protects vascular integrity, and prevents organ damage to restore homeostasis in critically ill patients.

Alloksys competes in the critical care space against companies developing targeted anti-inflammatories, anti-endotoxin therapies, and organ protectants. Its main differentiation is RESCAP®'s unique, broad-acting mechanism that simultaneously addresses multiple pathological pathways (detoxification, inflammation, endothelial leak) involved in critical illness, an approach distinct from most single-target competitors.